Skip to main content

Loading market data...

BMRN

BioMarin Pharmaceutical Inc.

NASDAQ • United states

$55.98

+$1.31

(+2.40%)

Source: Yahoo Finance · Quote time Oct 20, 2026 18:47 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

BioMarin Pharmaceutical Inc. (BMRN)

Unavailable

Quotes may be delayed

$10.84B

Market Cap

1,710,451

Volume

148.5

P/E Ratio

Unavailable

Div Yield

BioMarin Pharmaceutical Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 105 DIGITAL DRIVE, NOVATO, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

7 Oct 2026

BioMarin Pharmaceutical Inc. reported Operating or financial results

BioMarin Pharmaceutical Inc. filed an 8-K covering operating or financial results.

1 Oct 2026

BioMarin Pharmaceutical Inc. reported A material agreement

BioMarin Pharmaceutical Inc. filed an 8-K covering a material agreement.

15 Sep 2026

BioMarin Pharmaceutical Inc. reported Another company event

BioMarin Pharmaceutical Inc. filed an 8-K covering another company event.

14 Sep 2026

BioMarin Pharmaceutical Inc. reported A director or senior management change or compensation event

BioMarin Pharmaceutical Inc. filed an 8-K covering a director or senior management change or compensation event.

1 Sep 2026

BioMarin Pharmaceutical Inc. reported Another company event

BioMarin Pharmaceutical Inc. filed an 8-K covering another company event.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$874.01M

Total assets (USD)$11.72B

Total liabilities (USD)$5.40B

Shareholders' equity (USD)$6.32B

Long-term debt (USD)$3.53B

Debt due within a year (USD)$658.20M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$989.71M	$110.92M	$44.76M	$0.23	10-Q · 6 Aug 2026
Q1 2026	$766.21M	$129.64M	$105.53M	$0.54	10-Q · 5 May 2026
Q4 2025	$874.57M	−$44.61M	−$46.57M	Unavailable	10-K · 26 Feb 2026
Q3 2025	$776.13M	−$46.69M	−$30.74M	−$0.16	10-Q · 28 Oct 2025
Q2 2025	$825.41M	$276.89M	$240.53M	$1.23	10-Q · 5 Aug 2025
Q1 2025	$745.15M	$223.89M	$185.69M	$0.95	10-Q · 2 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $93.10

66.3% upside potential

📈

Strong Buy

Unavailable

👍

Buy

18

⏸️

Hold

5

📉

Sell

0

23 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 18:48 UTC Targets range 60.00–124.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

30

Sep 2026

Friberg Gregory R

EVP, Chief R&D Officer

Tax withholding

$60.00 per share

4,086 shares

10

Sep 2026

Plenge Robert M

Director

Grant or award

Unavailable per share

6,140 shares

2

Sep 2026

Davis George Eric

EVP, Chief Legal Officer

Open-market sale

$66.28 per share

17,557 shares

2

Jun 2026

Countouriotis Athena

Director

Grant or award

Unavailable per share

7,490 shares

2

Jun 2026

Walbert Timothy P

Director

Grant or award

Unavailable per share

7,490 shares

2

Jun 2026

Ho Maykin

Director

Grant or award

Unavailable per share

7,490 shares

2

Jun 2026

HOMBACH ROBERT J.

Director

Grant or award

Unavailable per share

7,490 shares

2

Jun 2026

Enyedy Mark J

Director

Grant or award

Unavailable per share

7,490 shares

Top Shareholders

Blackrock, Inc.

20,445,212 shares

3.163% change

6/30/2026

Vanguard Group Inc

18,127,847 shares

-2.447% change

12/31/2025

Dodge & Cox

14,844,930 shares

1.945% change

6/30/2026

Primecap Management Co/Ca/

14,190,183 shares

-0.027% change

6/30/2026

Vanguard Capital Management Llc

8,743,633 shares

1.162% change

6/30/2026

Vanguard Portfolio Management Llc

8,648,678 shares

4.22% change

6/30/2026

Norges Bank

8,207,954 shares

8.988% change

6/30/2026

State Street Corp

7,800,959 shares

6.935% change

6/30/2026

Viking Global Investors Lp

7,616,563 shares

7.852% change

6/30/2026

Vestal Point Capital, Lp

6,025,000 shares

68.531% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 18:48 UTC· 1 day ago

Research coverage and investment tools

BioMarin Pharmaceutical Inc. (BMRN) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$55.98 on 20 Oct 2026. That is 31% of the way from its 52-week low of US$49.26 to its 52-week high of US$70.98. Its market capitalisation was US$10.84 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$989.71M	$110.92M	$44.76M	$0.23	—	11.2%	$139.29M	10-Q · 6 Aug 2026 (opens in a new tab)
Q1 2026	$766.21M	$129.64M	$105.53M	$0.54	—	16.9%	$199.73M	10-Q · 5 May 2026 (opens in a new tab)
Q4 2025	$874.57M	−$44.61M	−$46.57M	Unavailable	—	-5.1%	$58.92M	10-K · 26 Feb 2026 (opens in a new tab)
Q3 2025	$776.13M	−$46.69M	−$30.74M	−$0.16	—	-6.0%	$340.24M	10-Q · 28 Oct 2025 (opens in a new tab)
Q2 2025	$825.41M	$276.89M	$240.53M	$1.23	—	33.5%	$168.17M	10-Q · 5 Aug 2025 (opens in a new tab)
Q1 2025	$745.15M	$223.89M	$185.69M	$0.95	—	30.0%	$157.63M	10-Q · 2 May 2025 (opens in a new tab)

Cash and equivalents: $874.01M
Total assets: $11.72B
Total liabilities: $5.40B
Shareholders' equity: $6.32B
Long-term debt: $3.53B
Debt due within a year: $658.20M

8-K · 7 Oct 2026

BioMarin Pharmaceutical Inc. reported Operating or financial results (opens in a new tab)

BioMarin Pharmaceutical Inc. filed an 8-K covering operating or financial results.
8-K · 1 Oct 2026 · Material agreement Signed

BioMarin Pharmaceutical Inc. reported A material agreement (opens in a new tab)

BioMarin Pharmaceutical Inc. filed an 8-K covering a material agreement.
8-K · 15 Sep 2026

BioMarin Pharmaceutical Inc. reported Another company event (opens in a new tab)

BioMarin Pharmaceutical Inc. filed an 8-K covering another company event.
8-K · 14 Sep 2026 · Management change

BioMarin Pharmaceutical Inc. reported A director or senior management change or compensation event (opens in a new tab)

BioMarin Pharmaceutical Inc. filed an 8-K covering a director or senior management change or compensation event.
8-K · 1 Sep 2026

BioMarin Pharmaceutical Inc. reported Another company event (opens in a new tab)

BioMarin Pharmaceutical Inc. filed an 8-K covering another company event.

Insider	Date	Transaction	Shares	Average price	Filing
Friberg Gregory R EVP, Chief R&D Officer	30 Sep 2026	Tax withholding (F)	−4,086	$60.00	Form 4 (opens in a new tab)
Plenge Robert M Director	10 Sep 2026	Grant or award (A)	+6,140	—	Form 4 (opens in a new tab)
Davis George Eric EVP, Chief Legal Officer	2 Sep 2026	Open-market sale (S)	−17,557	$66.28	Form 4 (opens in a new tab)
Countouriotis Athena Director	2 Jun 2026	Grant or award (A)	+7,490	—	Form 4 (opens in a new tab)
Walbert Timothy P Director	2 Jun 2026	Grant or award (A)	+7,490	—	Form 4 (opens in a new tab)
Ho Maykin Director	2 Jun 2026	Grant or award (A)	+7,490	—	Form 4 (opens in a new tab)
HOMBACH ROBERT J. Director	2 Jun 2026	Grant or award (A)	+7,490	—	Form 4 (opens in a new tab)
Enyedy Mark J Director	2 Jun 2026	Grant or award (A)	+7,490	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	20,445,212	3.163%
Vanguard Group Inc	12/31/2025	18,127,847	-2.447%
Dodge & Cox	6/30/2026	14,844,930	1.945%
Primecap Management Co/Ca/	6/30/2026	14,190,183	-0.027%
Vanguard Capital Management Llc	6/30/2026	8,743,633	1.162%
Vanguard Portfolio Management Llc	6/30/2026	8,648,678	4.22%
Norges Bank	6/30/2026	8,207,954	8.988%
State Street Corp	6/30/2026	7,800,959	6.935%
Viking Global Investors Lp	6/30/2026	7,616,563	7.852%
Vestal Point Capital, Lp	6/30/2026	6,025,000	68.531%

Previous close: 54.67 USD
Day range: 54.95 – 56.18 USD
52-week range: 49.26 – 70.98 USD
Volume: 1,710,451
Market cap: $10.84B
Average volume: 2,128,739
P/E ratio: 148.5
EPS (FY 2025, diluted): 1.80 USD
Shares outstanding: 193.57M
Beta (5Y monthly): 0.22

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 18:47 UTC· 1 day ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:22 UTC· 1 hour ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for BMRN yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.